Ultime notizie per Champions Oncology (NASDAQ:CSBR) Azioni

Champions Oncology

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

ADBE

CSBR

Scopri i 5 titoli da monitorare oggi, tra cui Kroger e Adobe, in attesa di dati trimestrali e movimenti chiave.

Pre-market: 5 titoli da monitorare oggi, 12 settembre 2024

Champions Oncology Inc

Champions Oncology, Inc. (CSBR) Q3 2024 Earnings Call Transcript

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Champions Oncology (CSBR – Research Report). The company's sha...

Craig-Hallum Sticks to Its Buy Rating for Champions Oncology (CSBR)

Champions Oncology Non-GAAP EPS of $0.01, revenue of $14M beats by $1.31M

Champions Oncology, Inc. (CSBR) Q4 2024 Earnings Call Transcript

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Champions Oncology</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/csbr-stock-quote/"><strong>CSBR</strong></a></span>) just reported results for the fourth quarter of 2024.</p><ul><li>Champions Oncology reported earnings per share of 1 cent. This was above the analyst estimate for EPS of -16 cents.</li><li>The company reported revenue of $14.00 million.</li><li>This was 10.33% better than the analyst estimate for revenue of $12.69 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/07/csbr-stock-earnings-champions-oncology-for-q4-of-2024/">CSBR Stock Earnings: Champions Oncology Beats EPS, Beats Revenue for Q4 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

CSBR Stock Earnings: Champions Oncology Beats EPS, Beats Revenue for Q4 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Harrow Health (HROW – Research Report), Accolade (AC...

Analysts Offer Insights on Healthcare Companies: Harrow Health (HROW), Accolade (ACCD) and Champions Oncology (CSBR)

Champions Oncology Non-GAAP EPS of $0.11 beats by $0.14, revenue of $14.06M beats by $0.83M

Champions Oncology, Inc. (CSBR) Q1 2025 Earnings Call Transcript

Champions Oncology upgraded to buy by Craig-Hallum

An update from Champions Oncology ( ($CSBR) ) is now available. Champions Oncology, Inc. has reported the unexpected passing of its President, Mr. ...

Champions Oncology Announces Sudden Loss of President

ACCD

HROW

Press Releases

Champions Oncology Reports Quarterly Revenue of $11.6 Million

Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 12, 2024

Champions Oncology's US Laboratory has Acquired Distinguished CAP Accreditation

Champions Oncology Reports Quarterly Revenue of $12.0 Million

Contracts

Champions Oncology and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development

Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 18, 2024

Champions Oncology Reports Quarterly Revenue of $14.0 Million

Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024

Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million

Comments

Champions Oncology

Notizie

Ultime notizie per Champions Oncology (NASDAQ:CSBR) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO